EP4041227A4 - A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers - Google Patents

A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers Download PDF

Info

Publication number
EP4041227A4
EP4041227A4 EP20886771.3A EP20886771A EP4041227A4 EP 4041227 A4 EP4041227 A4 EP 4041227A4 EP 20886771 A EP20886771 A EP 20886771A EP 4041227 A4 EP4041227 A4 EP 4041227A4
Authority
EP
European Patent Office
Prior art keywords
nanotechnologic
approach
novel
solid lipid
lipid carriers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20886771.3A
Other languages
German (de)
French (fr)
Other versions
EP4041227A1 (en
Inventor
Senay SANLIER
Güliz AK
Habibe YILMAZ
Ayse ÜNAL
Tugba KARAKAYALI
Özge SARI TURGUT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ege Universitesi
Original Assignee
Ege Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2020/07578A external-priority patent/TR202007578A2/en
Application filed by Ege Universitesi filed Critical Ege Universitesi
Publication of EP4041227A1 publication Critical patent/EP4041227A1/en
Publication of EP4041227A4 publication Critical patent/EP4041227A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20886771.3A 2019-11-11 2020-11-09 A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers Pending EP4041227A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR201917444 2019-11-11
TR2020/07578A TR202007578A2 (en) 2019-11-11 2020-05-14 A new nanotechnological approach with solid lipid carriers to treat glioblastoma
PCT/TR2020/051062 WO2021096464A1 (en) 2019-11-11 2020-11-09 A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers

Publications (2)

Publication Number Publication Date
EP4041227A1 EP4041227A1 (en) 2022-08-17
EP4041227A4 true EP4041227A4 (en) 2023-08-02

Family

ID=75912135

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20886771.3A Pending EP4041227A4 (en) 2019-11-11 2020-11-09 A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers

Country Status (2)

Country Link
EP (1) EP4041227A4 (en)
WO (1) WO2021096464A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114588277B (en) * 2022-04-07 2023-04-25 江苏省苏北人民医院 Construction method of polydopamine nano-particles loaded with temozolomide and Pep-1
WO2024074666A1 (en) * 2022-10-06 2024-04-11 Mireca Medicines Gmbh Conjugates for neuroretinal drug delivery

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANUPRIYA ANAND ET AL: "Brain targeted delivery of anticancer drugs: prospective approach using solid lipid nanoparticles", IET NANOBIOTECHNOLOGY, THE INSTITUTION OF ENGINEERING AND TECHNOLOGY, MICHAEL FARADAY HOUSE, SIX HILLS WAY, STEVENAGE, HERTS. SG1 2AY, UK, vol. 13, no. 4, 17 April 2019 (2019-04-17), pages 353 - 362, XP006109058, ISSN: 1751-8741, DOI: 10.1049/IET-NBT.2018.5322 *
DEVI REKHA ET AL: "Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis", ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 32, no. 10, 22 July 2015 (2015-07-22), pages 3137 - 3148, XP035537490, ISSN: 0724-8741, [retrieved on 20150722], DOI: 10.1007/S11095-015-1677-3 *
DUWA RAMESH ET AL: "Polymeric and lipid-based drug delivery systems for treatment of glioblastoma multiforme", JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, THE KOREAN SOCIETY OF INDUSTRIAL AND ENGINEERING CHEMISTRY, KOREA, vol. 79, 6 July 2019 (2019-07-06), pages 261 - 273, XP085824896, ISSN: 1226-086X, [retrieved on 20190706], DOI: 10.1016/J.JIEC.2019.06.050 *
MIRANDA ANA ET AL: "Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 531, no. 1, 9 August 2017 (2017-08-09), pages 389 - 410, XP085171863, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2017.07.049 *
See also references of WO2021096464A1 *
SENAY HAMARAT SANLIER ET AL: "In Vivo Biodistribution of Temozolomide and Carmustine Loaded Targeted Solid Lipid Nanoparticle", 26 October 2019 (2019-10-26), pages 175, XP009536054, Retrieved from the Internet <URL:https://www.ebatcongress.org/dosyalar/belge/9360_EBAT%202019%20ABSTRACT%20BOOK.pdf> *
VENISHETTY VINAY KUMAR ET AL: "β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, vol. 9, no. 3, 1 April 2013 (2013-04-01), AMSTERDAM, NL, pages 388 - 397, XP055823090, ISSN: 1549-9634, DOI: 10.1016/j.nano.2012.08.004 *

Also Published As

Publication number Publication date
EP4041227A1 (en) 2022-08-17
WO2021096464A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
SG11201401793PA (en) A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes
EP2661480A4 (en) Agglomeration-resistant desulfurizing product
EP3857529A4 (en) A vehicle-initiated approach to joining a group
EP3004362A4 (en) Recombinant microorganisms exhibiting increased flux through a fermentation pathway
EP2951466A4 (en) Spacer for belt tensioner
EP4041227A4 (en) A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers
EP3285565A4 (en) Macroalgae biomass production
WO2013011368A9 (en) Novel il-17r-ecd mutants
EP2761726A4 (en) Homopolar motor-generator
EP3004781A4 (en) Minigun with improved feeder sprocket and shaft
EP3019429A4 (en) Conveyor band drive system
EP3415612A4 (en) Planktonic strain of chlorella vulgaris for the production of edible biomass
EP3046856A4 (en) Conveyor chain support
EP3047028A4 (en) A fermentation process
EP2984018A4 (en) Chain drive system with polygon compensation
GB202002083D0 (en) Photodetectors
AU2011100333A4 (en) Polemount transformer for bushfire regions
AU2018900763A0 (en) Improvements in or relating to carriers
AU2018902218A0 (en) Improvements to Support Posts for Viticulture
AU2016903014A0 (en) A Novel Way to Monitor Internal Hay Conditions
AU2011904982A0 (en) Cellular structured product 2
AU2011904289A0 (en) Conveyor idler roller assembly
AU2011901273A0 (en) The Marlon Plug to Powerpoint Process
AU2012101534A4 (en) A compact luminaire
AU2012904837A0 (en) The macwell 100 group

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220510

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031418800

Ipc: A61K0047140000

A4 Supplementary search report drawn up and despatched

Effective date: 20230704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20230629BHEP

Ipc: A61K 31/17 20060101ALI20230629BHEP

Ipc: A61K 31/4188 20060101ALI20230629BHEP

Ipc: A61K 9/51 20060101ALI20230629BHEP

Ipc: A61K 47/14 20170101AFI20230629BHEP